入院时采集的肠道菌群与肝硬化患者结局之间的关联
研究纳入北美多家医院181例入院肝硬化患者,入院时采集粪便行16S rRNA测序并随访30天,发现肠道菌群β多样性与不良结局相关,变形菌门菌群与肝外器官衰竭、慢加急性肝衰竭及死亡风险升高相关,且独立于临床因素。
要点
- 入院时肠道菌群β多样性与肝硬化患者30天内不良结局相关,α多样性则相似。
- 变形菌门(肠杆菌科、弯曲菌科、巴斯德菌科)及厚壁菌门部分菌科与不良结局风险升高相关。
- 毛螺菌科和梭菌目等厚壁菌门菌群与不良结局风险降低相关。
核心结论
- 住院肝硬化患者入院时肠道菌群失调(尤其变形菌门成分变化)与肝外器官衰竭、慢加急性肝衰竭和死亡风险升高相关,且独立于临床因素。
研究设计与样本
- 研究纳入北美多家医院181例肝硬化患者,入院时采集粪便,随访30天,采用16S rRNA测序分析菌群,并用回归分析评估微生物与临床变量对各结局的作用。
主要发现
- 研究期间8%的患者发生慢加急性肝衰竭,16%转入重症监护,21%死亡。
- 有无不良结局的两组患者肠道菌群β多样性显著不同,α多样性相似。
- 发生慢加急性肝衰竭的患者肝硬化菌群失调比值(CDR)更低,合并肾衰竭者尤为明显。
- 变形菌门(肠杆菌科、弯曲菌科、巴斯德菌科)和厚壁菌门(肠球菌科、链球菌科)菌群与不良结局发生相关,而毛螺菌科和梭菌目等厚壁菌门菌群与不良结局风险降低相关。
- 菌群变化与肝外器官衰竭、转入重症监护、慢加急性肝衰竭和死亡的关联在logistic回归分析中独立于临床因素。
临床怎么用
- 作者认为,减少肠道菌群失调的策略可能改善肝硬化患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Inpatients with cirrhosis are prone to develop acute-on-chronic liver failure (ACLF). ACLF is associated with dysbiosis of the intestinal microbiota, which might serve as a prognostic factor. We investigated whether features of the intestinal microbiota associate organ failure, transfer to intensive care, and mortality within 30 days in patients admitted to the hospital with cirrhosis. METHODS: Stool samples were collected from 181 patients with cirrhosis (age 56 years; mean model for end-stage liver disease score, 21; 43% with infections) at time of admission, from multiple hospitals in North America. Patients were followed for 30 days for development of ACLF, extra-hepatic organ failures, and death or hospice care. Microbiota were analyzed by 16s rRNA sequencing for alpha diversity (within groups), beta diversity (between groups), cirrhosis dysbiosis ratio (CDR), and taxa that differed between groups with vs without negative outcomes (individual organ failures, transfer to intensive care, ACLF, death, or hospice). Regression analyses were performed using microbial and clinical variables for each outcome. RESULTS: ACLF developed in 8% of study subjects; 16% were transferred to intensive care and 21% died. Beta diversity of the intestinal microbiome was significantly different, whereas alpha diversity was similar, between subjects with vs without outcomes. The CDR was lower in subjects who developed ACLF, especially among those with renal failure. Taxa belonging to phylum Proteobacteria (Enterobacteriaceae, Campylobacteriaceae, and Pasteurellaceae) and Firmicutes (Enterococcaceae and Streptococcaceae) were associated with development of negative outcomes, whereas other Firmicutes members (Lachnospiraceae and Clostridiales) reduced risk of negative outcomes. Changes in the microbiota associated with extra-hepatic organ failure, transfer to intensive care, ACLF, and death, independently on logistic regression analyses. CONCLUSION: In hospitalized patients with cirrhosis, dysbiosis of the intestinal microbiota on admission (particularly changes in Protebacteria constituents) associates with increased risk of extra-hepatic organ failure, ACLF, and death, independent of clinical factors. Strategies to reduce gut dysbiosis might improve outcomes of patients with cirrhosis.
引用
- Bajaj JS, Vargas HE, Reddy KR, et al. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2018. PMID: 30036646. doi:10.1016/j.cgh.2018.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。